Head and neck cancer patient-derived xenograft models – A systematic review. (November 2020)

• Record Type: Journal Article
• Authors: Schuch, Lauren F.; Silveira, Felipe M.; Wagner, Vivian P.; Borgato, Gabriell B.; Rocha, Guilherme Z.; Castilho, Rogerio M.; Vargas, Pablo A.; Martins, Manoela D.
• Is Part Of: Critical reviews in oncology/hematology. Volume 155(2020)
• Publication Date: 2020-11
• Subjects: Xenograft model antitumor assays -- Head and neck neoplasms -- Animal models -- Preclinical drug evaluation -- Translational medical research; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2020.103087
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Highlights: This is the first systematic review that summarizes the use of HNC-PDX. In general, the studies were flawed in terms of detailing the procedures used. PDX recapitulates the histology and molecular aspects of the original HNC tumor. PDX represents a valuable method in translational research for the HNC. Abstract: Background: Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes. Methods: An electronic search was undertaken in four databases, including publications having used HNC-PDX. Data were analyzed descriptively. Results: 63 articles were yielded. The nude mouse was one most commonly animal model used (38.8 %), and squamous cell carcinoma accounted for the majority of HNC-PDX (80.6 %). Tumors were mostly implanted in the flank (86.3 %), and the latency period ranged from 30 to 401 days. The successful rate ranged from 17 % to 100 %. Different drugs and pathways were identified. Conclusion: HNC-PDX appears to significantly recapitulate the morphology of the original HNC and represents a valuable method in translational research for the assessment of the in vivo effect of novel therapies for HNC.